| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S80946-5mg买3赠1 |
99.40% | ￥152.00 |
8 | - | - | - | - |
|
S80946-10mg |
99.40% | ￥205.00 |
7 | - | - | - | - |
|
S80946-25mg |
99.40% | ￥274.00 |
7 | - | - | - | - |
|
S80946-50mg |
99.40% | ￥360.00 |
4 | - | - | - | - |
|
S80946-100mg |
≥98% | ￥690.00 |
货期：2-3天 | - | - | - | - |
|
S80946-200mg |
≥98% | ￥1240.00 |
货期：2-3天 | - | - | - | - |
|
| 产品描述： | GNF-5, the N-hydroxyethyl carboxamide analog of GNF-2, is an orally active Bcr-Abl inhibitor. GNF-5 has Bcr-Abl inhibition activity with an IC50 value of 0.22 µM. GNF-5 has good favorable pharmacokinetic properties. GNF-5 can be used for the research of kinds of cancer including chronic myelogenous leukemia (CML) and breast cancer | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | IC50: 0.22 µM (Abl);SARS-CoV;Bcr-Abl | ||||||||||||||||||||
| 体内研究： | GNF-5 (5 mg/kg iv. or 20 mg/kg oral) has suitable pharmacokinetic parameters. GNF-5 (oral, 50 or 100 mg/kg, twice daily, for 7 days) shows efficacious in vivo but can observe relapses. GNF-5 (75 mg/kg, b.i.d) inhibits T315I Bcr-Abl combination with nilotinib in vivo. | ||||||||||||||||||||
| 参考文献： | 1. Zhang J, et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature. 2010 Jan 28;463(7280):501-6. 2. Meirson T, et al. Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors. Oncotarget. 2018 Apr 24;9(31):22158-22183. | ||||||||||||||||||||
| 溶解性： | DMSO : ≥ 49 mg/mL (117.12 mM) | ||||||||||||||||||||
| 保存条件： | 2-8℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
